Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
Journal of Environmental Pathology, Toxicology and Oncology
Facteur d'impact: 1.625 Facteur d'impact sur 5 ans: 1.63 SJR: 0.402 SNIP: 0.613 CiteScore™: 2.3

ISSN Imprimer: 0731-8898
ISSN En ligne: 2162-6537

Journal of Environmental Pathology, Toxicology and Oncology

DOI: 10.1615/JEnvironPatholToxicolOncol.2017024619
pages 269-275

KAI1/CD82, Metastasis Suppressor Gene as a Therapeutic Target for Non-Small-Cell Lung Carcinoma

Venugopal Vinod Prabhu
Department of Biochemistry, University of Madras, Guindy campus, Chennai−600025, Tamil Nadu, India
S. Niranjali Devaraj
Department of Biochemistry, University of Madras, Guindy Campus, Chennai−600025, Tamil Nadu, India


Lung cancer is the most frequent malignancy and the leading cause of cancer-related death worldwide; it is the second most common cancer, comprising 1.69 million deaths worldwide per year. Among these, 85% of lung cancers are non-small-cell lung carcinoma (NSCLC). Metastasis is common in NSCLC patients and are responsible for most deaths. Kang-Ai 1 (KAI1), a tumor metastasis suppressor gene also known as Cluster of Differentiation 82 (CD82), is a member of the membrane tetraspanin protein family, which are capable of inhibiting the metastatic process in NSCLC. KAI1/CD82 suppresses metastasis via multiple mechanisms regulating inhibition of cell motility, adhesion, fusion, and proliferation. KAI1 may attenuate signaling to shut down metastatic colonization through attenuation of epidermal growth factor receptor (EGFR) signaling and inhibition of the Wnt signaling pathways. In this review, we focus on the differential expression of KAI1/CD82, a tumor metastasis suppressor gene that can inhibit cancer invasion and cell metastasis during NSCLC. The differential expression of KAI1/CD82 could prove to be of novel therapeutic significance in treating malignant tumors and in reducing their metastatic potential.

Articles with similar content:

Possible Role of Epidermal Growth Factor Receptors in the Therapy of Pancreatic Cancer
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.28, 2011, issue 4
R. S. R. Murthy, Suresh P. Vyas, Manish K. Gupta, Sahil Aggarwal, Swati Gupta
Iron Chelation: Inhibition of Key Signaling Pathways in the Induction of the Epithelial Mesenchymal Transition in Pancreatic Cancer and Other Tumors
Critical Reviews™ in Oncogenesis, Vol.18, 2013, issue 5
Alexander Richardson, Des R. Richardson, Zaklina Kovacevic
The Role of Oncogenic DNA Viruses in Penile Cancer Development
Critical Reviews™ in Oncogenesis, Vol.24, 2019, issue 4
Silvia Maria Baeta Cavalcanti, Katia Cristina da Silva, Willker Menezes da Rocha
Molecular Mechanisms and Therapeutic Potential of miR-493 in Cancer
Critical Reviews™ in Eukaryotic Gene Expression, Vol.29, 2019, issue 6
Lingwei Huang, Qing Wei, Lingli Huang, Ziwei Li
Glioblastoma Multiforme: The Genetic Perspective of the Treatment Planning
Critical Reviews™ in Eukaryotic Gene Expression, Vol.25, 2015, issue 4
Rasime Kalkan